We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access to RXDX-105 for Cancers With RET Alterations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03052569
Expanded Access Status : No longer available
First Posted : February 14, 2017
Last Update Posted : April 26, 2019
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
Expanded access to RXDX-105 will be given to patients with cancers harboring RET alterations who have not received TKIs that target RET alterations, who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for RXDX-105.

Condition or disease Intervention/treatment
Cancers With RET Alterations Drug: RXDX-105

Layout table for study information
Study Type : Expanded Access
Official Title: Expanded Access to RXDX-105 for the Treatment of Cancers With RET Alterations

Resource links provided by the National Library of Medicine



Intervention Details:
  • Drug: RXDX-105
    Oral Capsules

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Diagnosis of advanced cancer with RET alterations
  • Unable to participate in an ongoing RXDX-105 clinical trial
  • Willing and able to provide written, signed informed consent
  • Medically suitable for treatment with RXDX-105

Exclusion Criteria:

  • Prior treatment with a TKI that has activity against RET alterations
  • Currently enrolled in an ongoing clinical study with any other investigational agent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03052569


Locations
Layout table for location information
United States, California
Www.Ignyta.Com
San Diego, California, United States, 92121
Sponsors and Collaborators
Hoffmann-La Roche
Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT03052569    
Other Study ID Numbers: RXDX-105 - EAP
First Posted: February 14, 2017    Key Record Dates
Last Update Posted: April 26, 2019
Last Verified: April 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Agerafenib
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action